Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ET-01 in Lateral Canthal Lines
NCT03912805Phase 2Completed
- Sponsor
- Eirion Therapeutics
- Start
- Feb 2019
- Primary completion
- May 2019
- Modality
- CRISPR-Cas9, Gene Silencing, Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in lateral canthal rhytides comparing Vehicle with ET-01 1610U (2 arms). Primary endpoint: Number of Participants With a Response Defined as Change in IGA-C Score by at Least 2 Ordinals at Week 4. Started Feb 2019; status: completed.
02
Drugs
ET-01
03
Conditions
lateral canthal rhytides
Beyond the preview
Go deeper on NCT03912805.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03912805.